Alternatively, the chosen time-point for pretreatment with ERW1041E (set at 30 min prior to tracer administration) might not be optimal for full TG2 inhibition, although at this similar time-point a reduction of TG2 activity by a factor of four in a pulmonary hypertension model was observed [9]. Here, TGM2 is linked to pulmonary arterial hypertension.